Phexxi (Lactic Acid/Citric/Potassium) Patent Expiration, LOE Window & CMS Spending

Phexxi (Lactic Acid/Citric/Potassium) by Evofem Bioscien: Off-Patent Genericized (AB Competition), 0 AB generics, $6.6M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEvofem Bioscien
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$6.6M
2024 Medicare Part D Spend$82K
2024 Medicaid Spend$6.5M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 18.4% 2-yr change)